SAN JOSE, Calif., Sept. 6 /PRNewswire/ -- Stem Cell RegenCo, a Silicon Valley, California company, and IIBM, one of the world’s top stem cell research groups, have entered into an exclusive joint venture giving liver damage patients a crucial alternative to a dangerous and uncertain liver transplant. IIBM is headed by Gennady T. Sukhikh, MD, who, according to a Google computer search, is one of the world’s foremost stem cell research specialists.
The focus of the agreement is to extend IIBM’s newly developed and clinically proven STEM CELL LIVER REGENERATION (SCLR) procedure to the western world where due to the ban on embryonic stem cell research none currently exists. A dangerous liver transplant is now the only treatment for acute and chronic liver failure. The problems with these transplants are threefold: (1) there is a severe shortage of donor organs and thousands of patients die each year while awaiting an available donor liver; (2) the very great possibility the patient’s body will reject the foreign liver; (3) even if the liver is not rejected the patients spend the rest of their lives on immuno-suppression drugs. These powerful drugs leave liver recipients open to infection and increase the risk of heart disease or cancer later in life. The cost of such drugs alone is more than $10,000 per year for life.
With the IIBM developed, non-invasive stem cell regeneration procedure, none of the above factors apply - no rejection possibilities, no immuno- suppression drugs or costs. Shortly after the procedure, the patient will have a regenerated liver that replaces the old Hep B, C, cirrhosis or other diseased liver. As confirmed by a multitude of clinical trials this procedure is effective and safe even in extreme emergencies such as end-stage liver disease.
Due to its non-surgical nature, it is particularly effective for treatment of children’s liver problems.
The costs, which are not covered by insurance, are less than one/fifth that of a standard liver transplant. For complete information, visit the website http://www.stemcellregenco.com or phone toll-free 1-866-795-4876.
Due to U.S. legal restrictions on stem cells the procedure will take place in the top Moscow hospital. The patient flies overnight first class from the U.S. in a Boeing 767, is picked up at the Moscow International airport by limo, or ambulance if necessary, and taken directly to the hospital where after a thorough examination and preparation the stem cell procedure is performed. The patient has an English-speaking staff at all times.
All costs, including round-trip airline fare from LA or NY to Moscow, seven-day hospital stay, physician costs, hospital medicine, etc., are included in the total price of $50,000. Four U.S. patients per month will be accepted for this special life-saving treatment beginning in early September 2006. Treatments will be given in order of application and acceptance.
Media Contact:
Jan Stevens, Stem Cell RegenCo 1-408-269-0445
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Source: Stem Cell RegenCo
